Peer Exchange

Panelists discuss how acute myeloid leukemia treatment has evolved from a one-size-fits-all approach to personalized medicine incorporating genetic profiling, targeted therapies like venetoclax and IDH inhibitors, emerging oral regimens, and comprehensive patient assessments that consider not only traditional fitness criteria but also social determinants of health, quality of life factors, and the potential for curative versus palliative care in different patient populations.

Panelists discuss how heart failure management has evolved from limited treatment options to a comprehensive approach requiring multidisciplinary collaboration, early intervention strategies, and integration of multiple evidence-based therapies including SGLT2 inhibitors, ARNIs, and mineralocorticoid receptor antagonists to address the substantial clinical and economic burden of this condition affecting millions of Americans.

Ryan Haumschild, PharmD, MS, MBA, CPEL; Andrew Alexis, MD, MPH; April W. Armstrong, MD, MPH; Andrew M. Mastro, MS, PA-C; and Mark Makhinson, PharmD, discuss how atopic dermatitis is an immune-mediated disease with heterogeneous pathways that present differently across skin tones, requiring health care professionals to recognize diverse clinical manifestations, address educational gaps in understanding the complex immunopathogenesis, and ensure equitable access to targeted biologic therapies through improved training, clinical trial representation, and coordinated care teams.

Panelists describe the aggressive clinical and molecular features of KMT2A-rearranged acute myeloid leukemia (AML)—including its menin-dependent biology and poor response to standard chemotherapy—while evaluating current and emerging therapies like Menin inhibitors, and highlighting persistent challenges in early diagnosis, equitable access, and delivering specialized care across health care settings.

4 experts in this video

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Ryan Haumschild, PharmD, MBA, MS; Faith Davies, MD; Shachar Peles, MD, and Sagar Lonial MD, FACP discuss how quadruple therapy regimens incorporating CD38 antibodies have become the standard of care for both transplant-eligible and transplant-ineligible multiple myeloma patients, with treatment decisions guided by patient risk stratification, minimal residual disease monitoring, and the balance between achieving deep responses and maintaining quality of life.

Nihar Desai, MD, MPH; Kenny J. Cole, MD, MS; Jacinda Mawson Nicklas, MD, MPH, MA; Esra Karslioglu French, MD, MBA, and Goutham Rao, MD, discuss how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity by enabling a paradigm shift from reactive glucose management to proactive weight-focused care that addresses the root causes of cardiometabolic disease, while emphasizing the critical need for multidisciplinary teams, bias-free patient communication, and systematic healthcare delivery changes to overcome barriers like provider time constraints, medication access, and weight stigma.

Julie A. Parsons, MD; John Brandsema, MD; and Tina Duong, MPT, PhD, discuss how management approaches for older patients with spinal muscular atrophy (SMA) differ from those for infants, highlighting the importance of individualized treatment goals focused on independence, fatigue management, quality of life, and the challenges of measuring outcomes with currently available assessment tools, while also exploring current and emerging therapies, including splice modifiers and potential intrathecal gene therapy options.

Ryan Haumschild, PharmD, MS, MBA, CPEL; Elizabeth Castronovo, NP; Martin Dietrich, MD, PhD; Mary Grizzard, MSN, FNP; and Christine M. Lovly, MD, PhD, FASCO, discuss how advances in ALK-positive non–small cell lung cancer (ALK+ NSCLC) treatment, including 5-year CROWN trial data for lorlatinib, recent ensartinib approval, comparative efficacy against brain metastases, toxicity management strategies, and sequencing approaches following progression are reshaping clinical decision-making to optimize long-term patient outcomes.

Panelists discuss how the latest data from the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024) on bispecific therapies for B-cell lymphomas, including epcoritamab, mosunetuzumab, and odronextamab, influence treatment strategies, address toxicity management, and highlight the challenges and opportunities in expanding access to these therapies across academic and community settings.

Ryan Haumschild, PharmD, MS, MBA, CPEL; Gerald Appel, MD; Andrew S. Bomback, MD; and Jared Hassler, MD, discuss IgA nephropathy, a progressive kidney disease characterized by IgA antibody deposits in the mesangium, examining its 4-hit pathogenesis cascade, clinical presentation, diagnostic challenges, treatment evolution from supportive care to targeted therapies addressing specific disease mechanisms, economic impact across disease stages, and the importance of early intervention to delay progression to end-stage kidney disease while improving patient outcomes and quality of life.

Ryan Haumschild, PharmD, MS, MBA; Thomas M. Hooton, MD; Wendy Cheng, PhD, MPH; Debra Fromer, MD; and Katie S. Murray, DO, discuss how uncomplicated urinary tract infection (UTI) management is evolving through new antibiotics such as pivmecillinam, sulopenem etzadroxil/probenecid, and gepotidacin to address growing resistance issues while emphasizing personalized approaches, prevention strategies, antimicrobial stewardship, and the socioeconomic impact of treatment failures across diverse patient populations.

Experts discuss recent bispecific antibody approvals and clinical applications, address operational challenges in implementation—including barriers in community practice and the management of cytokine release syndrome—and consider the potential of these therapies in expanding treatment options and improving patient access.

Kavita V. Nair, PhD; B. Joy Snider, MD, PhD; Cynthia Lawlor, MD, MPH; and Rhonna Shatz, DO, discuss how Alzheimer disease management is evolving through improved screening, specialized care pathways, emerging amyloid-targeting therapies, standardized monitoring approaches, and strategies to address financial barriers while maintaining optimism for future treatment advances.

A discussion exploring how bronchiectasis involves a vicious cycle of airway damage, where neutrophilic inflammation leads to bronchial wall destruction and dilation, while explaining that diagnosis relies primarily on high-resolution CT imaging showing bronchial wall thickening and dilated airways, distinguishing it from COPD's emphysematous changes.

Melody Chang, MBA, RPh, BCOP; Andre D. Harvin, PharmD, MS, MBA; Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO; Brian Mulherin, MD; and Ashley Hall, PharmD, discuss comprehensive approaches to iron deficiency anemia (IDA), from its pathophysiology and diagnosis through various treatment options such as oral and intravenous iron formulations, while addressing challenges such as hypophosphatemia, treatment adherence, insurance barriers, and future directions in patient care, emphasizing the importance of individualized treatment strategies and monitoring protocols to optimize outcomes.

Panelists discuss how recent advancements, particularly the introduction of Janus kinase JAK inhibitors, are reshaping the treatment landscape for Aalopecia Aareata, offering new therapeutic options and addressing unmet needs in both efficacy and patient care.

Callie Coombs, MD; Matthew Davids, MD, MMSc; Seema Bhat, MD; and Lori Leslie, MD, discuss venetoclax-obinutuzumab therapy, pirtobrutinib’s progression-free survival data from the BRUIN CLL-321 trial at ASH 2024, Bruton tyrosine kinase (BTK) inhibitor safety profiles, cost considerations under the Inflation Reduction Act, and clinical strategies for managing BTK inhibitor toxicity.

Ryan Haumschild, PharmD, MS, MBA; Anne Chiang, MD, PhD; Afshin Dowlati, MD; Jacob Sands, MD; and Wade Iams, MD, explore recent advances in small cell lung cancer (SCLC) management, discussing staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery.

Ryan Haumschild, PharmD, MS, MBA; Anne Chiang, MD, PhD; Afshin Dowlati, MD; Jacob Sands, MD; and Wade Iams, MD, explore recent advances in small cell lung cancer (SCLC) management, discussing staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery.


Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo